Literature DB >> 17898066

Atraumatic oral spray immunization with replication-deficient viral vector vaccines.

Christiane Stahl-Hennig1, Seraphin Kuate, Monika Franz, You S Suh, Heribert Stoiber, Ulrike Sauermann, Klara Tenner-Racz, Stephen Norley, Ki S Park, Young C Sung, Ralph Steinman, Paul Racz, Klaus Uberla.   

Abstract

The development of needle-free vaccines is one of the recently defined "grand challenges in global health" (H. Varmus, R. Klausner, R. Klausner, R. Zerhouni, T. Acharya, A. S. Daar, and P. A. Singer, Science 302:398-399, 2003). To explore whether a natural pathway to the inductive site of the mucosa-associated lymphatic tissue could be exploited for atraumatic immunization purposes, replication-deficient viral vector vaccines were sprayed directly onto the tonsils of rhesus macaques. Tonsillar immunization with viral vector vaccines encoding simian immunodeficiency virus (SIV) antigens induced cellular and humoral immune responses. Viral RNA levels after a stringent SIV challenge were reduced, providing a level of protection similar to that observed after systemic immunization with the same vaccines. Thus, atraumatic oral spray immunization with replication-deficient vectors can overcome the epithelial barrier, deliver the vaccine antigen to the mucosa-associated lymphatic tissue, and avoid induction of tolerance, providing a novel approach to circumvent acceptability problems of syringe and needle vaccines for children and in developing countries.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17898066      PMCID: PMC2169087          DOI: 10.1128/JVI.01400-07

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  43 in total

1.  Public health. Grand Challenges in Global Health.

Authors:  H Varmus; R Klausner; E Zerhouni; T Acharya; A S Daar; P A Singer
Journal:  Science       Date:  2003-10-17       Impact factor: 47.728

2.  Replication-defective vector based on a chimpanzee adenovirus.

Authors:  S F Farina; G P Gao; Z Q Xiang; J J Rux; R M Burnett; M R Alvira; J Marsh; H C Ertl; J M Wilson
Journal:  J Virol       Date:  2001-12       Impact factor: 5.103

3.  Mutations within the putative membrane-spanning domain of the simian immunodeficiency virus transmembrane glycoprotein define the minimal requirements for fusion, incorporation, and infectivity.

Authors:  J T West; P B Johnston; S R Dubay; E Hunter
Journal:  J Virol       Date:  2001-10       Impact factor: 5.103

4.  Transfer of primer binding site-mutated simian immunodeficiency virus vectors by genetically engineered artificial and hybrid tRNA-like primers.

Authors:  A C Hansen; T Grunwald; A H Lund; A Schmitz; M Duch; K Uberla; F S Pedersen
Journal:  J Virol       Date:  2001-05       Impact factor: 5.103

5.  Transport of human immunodeficiency virus type 1 pseudoviruses across the blood-brain barrier: role of envelope proteins and adsorptive endocytosis.

Authors:  W A Banks; E O Freed; K M Wolf; S M Robinson; M Franko; V B Kumar
Journal:  J Virol       Date:  2001-05       Impact factor: 5.103

6.  Dendritic cells, infected with vesicular stomatitis virus-pseudotyped HIV-1, present viral antigens to CD4+ and CD8+ T cells from HIV-1-infected individuals.

Authors:  A Granelli-Piperno; L Zhong; P Haslett; J Jacobson; R M Steinman
Journal:  J Immunol       Date:  2000-12-01       Impact factor: 5.422

7.  Early protection against pathogenic virus infection at a mucosal challenge site after vaccination with attenuated simian immunodeficiency virus.

Authors:  Klara Tenner-Racz; Christiane Stahl Hennig; Klaus Uberla; Heribert Stoiber; Ralf Ignatius; Jonathan Heeney; Ralph M Steinman; Paul Racz
Journal:  Proc Natl Acad Sci U S A       Date:  2004-02-17       Impact factor: 11.205

8.  Recombinant modified vaccinia virus Ankara provides durable protection against disease caused by an immunodeficiency virus as well as long-term immunity to an orthopoxvirus in a non-human primate.

Authors:  Patricia L Earl; Jeffrey L Americo; Linda S Wyatt; Leigh Anne Eller; David C Montefiori; Russ Byrum; Michael Piatak; Jeffrey D Lifson; Rama Rao Amara; Harriet L Robinson; John W Huggins; Bernard Moss
Journal:  Virology       Date:  2007-05-11       Impact factor: 3.616

9.  Immunogenicity of recombinant adenovirus serotype 35 vaccine in the presence of pre-existing anti-Ad5 immunity.

Authors:  Dan H Barouch; Maria G Pau; Jerome H H V Custers; Wouter Koudstaal; Stefan Kostense; Menzo J E Havenga; Diana M Truitt; Shawn M Sumida; Michael G Kishko; Janelle C Arthur; Birgit Korioth-Schmitz; Michael H Newberg; Darci A Gorgone; Michelle A Lifton; Dennis L Panicali; Gary J Nabel; Norman L Letvin; Jaap Goudsmit
Journal:  J Immunol       Date:  2004-05-15       Impact factor: 5.422

10.  A human immunodeficiency virus 1 (HIV-1) clade A vaccine in clinical trials: stimulation of HIV-specific T-cell responses by DNA and recombinant modified vaccinia virus Ankara (MVA) vaccines in humans.

Authors:  Matilu Mwau; Inese Cebere; Julian Sutton; Priscilla Chikoti; Nicola Winstone; Edmund G-T Wee; Tara Beattie; Yun-Hsiang Chen; Lucy Dorrell; Helen McShane; Claudia Schmidt; Mary Brooks; Sandip Patel; Joanna Roberts; Christopher Conlon; Sarah L Rowland-Jones; Job J Bwayo; Andrew J McMichael; Tomáš Hanke
Journal:  J Gen Virol       Date:  2004-04       Impact factor: 3.891

View more
  18 in total

Review 1.  Microneedle-Mediated Vaccine Delivery to the Oral Mucosa.

Authors:  Rachel L Creighton; Kim A Woodrow
Journal:  Adv Healthc Mater       Date:  2018-12-10       Impact factor: 9.933

2.  Novel vaccine regimen elicits strong airway immune responses and control of respiratory syncytial virus in nonhuman primates.

Authors:  Thomas Grunwald; Matthias Tenbusch; Reiner Schulte; Katharina Raue; Hans Wolf; Drew Hannaman; Rik L de Swart; Klaus Uberla; Christiane Stahl-Hennig
Journal:  J Virol       Date:  2014-01-22       Impact factor: 5.103

Review 3.  Non-invasive administration of biodegradable nano-carrier vaccines.

Authors:  Mohd Abul Kalam; Abdul Arif Khan; Aws Alshamsan
Journal:  Am J Transl Res       Date:  2017-01-15       Impact factor: 4.060

4.  Oral Immunization with Recombinant Vaccinia Virus Prime and Intramuscular Protein Boost Provides Protection against Intrarectal Simian-Human Immunodeficiency Virus Challenge in Macaques.

Authors:  Rajesh Thippeshappa; Baoping Tian; Brad Cleveland; Wenjin Guo; Patricia Polacino; Shiu-Lok Hu
Journal:  Clin Vaccine Immunol       Date:  2015-12-30

5.  Delivery of human immunodeficiency virus vaccine vectors to the intestine induces enhanced mucosal cellular immunity.

Authors:  Lingshu Wang; Cheng Cheng; Sung-Youl Ko; Wing-Pui Kong; Masaru Kanekiyo; David Einfeld; Richard M Schwartz; C Richter King; Jason G D Gall; Gary J Nabel
Journal:  J Virol       Date:  2009-05-06       Impact factor: 5.103

Review 6.  Oral manifestations associated with HIV infection.

Authors:  Mostafa Nokta
Journal:  Curr HIV/AIDS Rep       Date:  2008-02       Impact factor: 5.071

7.  Role of complement and antibodies in controlling infection with pathogenic simian immunodeficiency virus (SIV) in macaques vaccinated with replication-deficient viral vectors.

Authors:  Barbara Falkensammer; Barbara Rubner; Alexander Hiltgartner; Doris Wilflingseder; Christiane Stahl Hennig; Seraphin Kuate; Klaus Uberla; Stephen Norley; Alexander Strasak; Paul Racz; Heribert Stoiber
Journal:  Retrovirology       Date:  2009-06-21       Impact factor: 4.602

8.  Enhancement of the priming efficacy of DNA vaccines encoding dendritic cell-targeted antigens by synergistic toll-like receptor ligands.

Authors:  Claudius Grossmann; Matthias Tenbusch; Godwin Nchinda; Vladimir Temchura; Ghulam Nabi; Geoffrey W Stone; Richard S Kornbluth; Klaus Uberla
Journal:  BMC Immunol       Date:  2009-08-03       Impact factor: 3.615

9.  Sang Froid in a time of trouble: is a vaccine against HIV possible?

Authors:  Stanley A Plotkin
Journal:  J Int AIDS Soc       Date:  2009-02-02       Impact factor: 5.396

10.  Immunization with single-cycle SIV significantly reduces viral loads after an intravenous challenge with SIV(mac)239.

Authors:  Bin Jia; Sharon K Ng; M Quinn DeGottardi; Michael Piatak; Eloísa Yuste; Angela Carville; Keith G Mansfield; Wenjun Li; Barbra A Richardson; Jeffrey D Lifson; David T Evans
Journal:  PLoS Pathog       Date:  2009-01-23       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.